BioSpace News Archive

Airway Therapeutics, Inc. announced it successfully completed enrollment in its Phase 1b trial of zelpultide alfa for preventive use in very preterm infants at risk for bronchopulmonary dysplasia.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies 2023 Global Healthcare Conference on Thursday, June 8, 2023 at 3:00 p.m. Eastern Time.

Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced the appointment of William Pedranti, J.D., as Chief Executive Officer.

Lotus Pharmaceuticals (1795:TT; “Lotus”) and NRx Pharmaceuticals Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals or NRx”), a clinical stage biopharmaceutical company, today announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, announced that the company is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on Thursday, June 15, 2023, at 11:00 a.m. EDT.

Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an oral presentation at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced the presentation of data detailing the mechanism of action and pharmacokinetics of TNX-601 ER (tianeptine hemioxalate extended release) and TNX-4300 (estianeptine) at the American Society of Clinical Psychopharmacology (ASCP) meeting in Miami, Fla.

Ocugen, Inc. announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.

Krystal Biotech, Inc. a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced that the Company will participate in the following upcoming investor conferences.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZ is now commercially available.